

**Metabolic Endocrine Education Foundation (MEEF)
638 Lindero Canyon Dr Suite # 380
Oak Park, CA 91377**


NONPROFIT
ORG
US POSTAGE PAID
VAN NUYS, CA
PERMIT # 659

Register Online: www.wcir.org/registration

CME Symposium **22nd** IN ASSOCIATION WITH THE **WCIRDC**

EARN
FREE CME
ABIM-MOC
CREDITS
1.50

T1D Circa 2024 Managing Obesity, CardioRenal Complications & Hyperglycemia



DIABETES
TYPE 1

Friday, December 13, 2024
6:00 pm – 7:30 pm PST
Hilton Universal City Hotel
Los Angeles, California
DINNER WILL BE SERVED

All content available ON-DEMAND for ONE YEAR following the meeting.

This is a CME Symposium Supported by an Educational Grant from **Lexicon**
Free for all 22nd WCIRDC attendees. Register online: www.wcir.org/registration
This CME Symposium will be available and FREE for ONE year following the meeting.

Provided By:



Administered By:





T1D CIRCA 2024 – MANAGING OBESITY, CARDIORENAL COMPLICATIONS & HYPERGLYCEMIA

CHAIRS: **Matthew J. Budoff, MD • Yehuda Handelsman, MD**

6:00 pm – 7:30 pm	DINNER CME SYMPOSIUM	Supported by Lexicon	Sierra Ballroom B
6:00 pm	Dinner and Wine Served		
6:10 pm	Introduction & Pre-CME Questions Matthew J. Budoff, MD		
6:15 pm	Controlling Hyperglycemia in Today's T1D- Challenges and Solutions Richard E. Pratley, MD		
6:30 pm	Contemporary T1D- Obesity and Cardiometabolic Complications Matthew J. Budoff, MD		
6:45 pm	CKD in T1D the role of the SGLT1 /2i Sotgliflozin David Cherney MD, PhD		
7:05 pm	Panel Discussion and Q&A: Risk Benefit- Managing T1D with Non-Insulin Agents Preventing Cardiorenal Morbidities Panel: Matthew J. Budoff, MD • David Cherney MD, PhD Richard E. Pratley, MD Moderator: Yehuda Handelsman, MD		
7:30 pm	Post-CME Questions & Concluding Remarks Adjourn		

Program Description

In 2024 patients with Type 1 Diabetes (T1D) are, unlike in the past, largely overweight or obese. The high prevalence of kidney and heart disease among individuals with T1D are of significant concerns, as these conditions are among the leading causes of morbidity and mortality in this population. Chronic kidney disease (CKD,) cardiovascular disease (CVD) and Heart Failure (HF) are common complications of T1D not only due to the long-term effects of hyperglycemia but also due to obesity, fat and insulin resistance.

In this CME satellite symposium session, we will explore the changing landscape of T1D addressing the need for new therapies in this population to improve glucose control And prevent cardiorenal complications. We will address the gaps in physicians' knowledge on the emerging role of sotagliflozin an SGLT2/1-i in the management of these patients, recognizing the significant long term benefit on Morbidities and Longevity while mitigating the potential manageable risk.

Learning Objectives

Upon completion of this CME symposium, participants should be able to:

- Discuss the epidemiology of Obesity and CardioRenal complications in T1D
- Understand the Pathophysiology of HF & CKD in T1D
- Be Aware of the Difficulty to Control Hyperglycemia in the Obese T1D patients and the Potential Role of Non-Insulin Agents in these challenging patients
- Describe the benefit of using SGLT2/1i in T1D to protect and improve Kidney Function

Target Audience

This educational initiative is designed for cardiologists, endocrinologists, nephrologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of people with Heart failure or Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

FACULTY



Matthew J. Budoff, MD, FACC, FAHA, Chair
Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology, Lundquist Institute at Harbor-UCLA Medical Center
Program Director of Cardiac CT, Division of Cardiology
Harbor-UCLA Medical Center
Torrance, California



Yehuda Handelsman, MD, FACP, FNLA, FASPC, FAHA, MACE, Chair
Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory board, DCMi- Diabetes CardioRenal & Metabolism Institute
Chair & Program Director, WCIRDC- 22nd World Congress on IR, DM & CVD
Tarzana, California



Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director, Advent Health Diabetes Institute
Senior Investigator and Diabetes Program Lead
Advent Health Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida



David Cherney, MD, PhD
Professor of Medicine
Clinician Scientist - Division of Nephrology
University Health Network
Senior Scientist
Toronto General Hospital Research Institute
Director, Renal Physiology Laboratory
University Health Network
Toronto, Ontario

CME DINNER SYMPOSIUM

This CME symposium is FREE for 22nd WCIRDC attendees and will stay on-demand for ONE year following the meeting.
Learn more: WCIR.ORG/CMESymposium

To register for the entire 22nd WCIRDC meeting
Please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc., designated this live educational activity for a maximum of 1.50 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact:

info@tmioa.com or 818 342 1889

This is a CME Program Supported by an Educational Grant from **Lexicon**